Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Search
Search
  1. ESMO
  2. Guidelines
  3. ESMO-MCBS

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 17
4 95
3 125
2 34
1 19
Curative setting
A 38
C 2
ESMO-MCBS Scores by tumour type
Non-curative setting
Breast Cancer 28
Central Nervous System Malignancies 0
Endocrine Tumours 19
Gastrointestinal Cancers 53
Genitourinary Cancers 51
Gynaecological Malignancies 30
Head and neck cancer 6
Refractory NTRK fusion–positive cancers 2
Sarcoma 10
Skin Cancers 24
TMB-H solid tumours 1
Thoracic Malignancies 65
dMMR/MSI-H solid tumours 1
Curative setting
Breast Cancer 8
Central Nervous System Malignancies 1
Endocrine Tumours 0
Gastrointestinal Cancers 15
Genitourinary Cancers 4
Gynaecological Malignancies 0
Head and neck cancer 0
Refractory NTRK fusion–positive cancers 0
Sarcoma 2
Skin Cancers 8
TMB-H solid tumours 0
Thoracic Malignancies 2
dMMR/MSI-H solid tumours 0

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

reset selection
Evaluation form 1 For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in “orphan diseases” and for diseases with “high unmet need” when primary outcome is PFS or ORR.

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Pembrolizumab ChT Placebo plus ChT In combination with ChT as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early‑stage triple‑negative breast cancer at high risk of recurrence Breast Cancer Breast Cancer Triple-negative KEYNOTE-522
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Nivolumab - Placebo High-risk muscle-invasive urothelial carcinoma after radical surgery Genitourinary Cancers Urothelial Carcinoma - CHECKMATE-274
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Atezolizumab - Best supportive care Adjuvant treatment following resection and platinum-based ChT for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥1% of tumor cells Thoracic Malignancies Non-small-cell Lung Cancer PD-L1 ≥1% IMpower010
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Abemaciclib Standard endocrine therapy (aromatase inhibitors and/or antiestrogens with or without ovarian suppression) Standard endocrine therapy In combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor positive, HER2-negative, node positive early breast cancer at high risk of recurrence. In pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone agonist. Breast Cancer Breast Cancer HR+ HER2- node-positive Ki-67 score ≥20% monarchE
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Pembrolizumab - Placebo Adjuvant treatment of RCC for patients with increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions Genitourinary Cancers Renal cell cancer - KEYNOTE-564
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Nivolumab - Placebo Adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression ≥1%, who are at high risk of recurrence after undergoing radical resection of MIUC Genitourinary Cancers Urothelial Carcinoma PD-L1 expression ≥1% CheckMate 274
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Nivolumab - Placebo Adjuvant High-risk muscle-invasive urothelial carcinoma after radical surgery Genitourinary Cancers Urothelial Carcinoma - CheckMate 274
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Olaparib - Placebo Adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant ChT Breast Cancer Breast Cancer gBRCAm HER2-negative OlympiA
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.